Wegovy Weight Loss: Dosage and What to Expect

Wegovy is a prescription medicine used for weight management alongside a reduced-calorie diet and increased physical activity. For many adults, treatment involves gradually increasing the weekly dose towards the standard 2.4 mg maintenance dose. A higher 7.2 mg weekly option is also authorised in the UK for certain adults with obesity. The appropriate dose depends on the licensed indication, individual response and tolerability, and should always be guided by a prescriber.

If you're wondering whether a specific milligram figure is the “right” one to aim for, the honest answer is more individual than a single number. Understanding how Wegovy works, what results may be seen at different doses, including the 7.2mg option, how response can vary from person to person, how to start treatment in the UK, and the key safety points and common questions around treatment helps set realistic expectations and supports safer, better-informed use under medical supervision.

Key things to know

Wegovy's licensed weight-management outcomes are based on trial data at the standard 2.4mg maintenance dose specifically.

The lower titration doses (0.25mg to 1.7mg) are stepping stones toward the maintenance dose, not final therapeutic targets in their own right.

• Higher doses are generally associated with greater average weight loss at a population level, though individual response varies considerably.
• Some people do experience meaningful results before reaching the full maintenance dose, and this is an individual, prescriber-guided decision.
• A 7.2 mg once-weekly dose is authorised for certain adults with obesity (BMI of 30 kg/m² or higher). It is not the routine next step for everyone taking Wegovy, and eligibility depends on the licensed indication and prescriber's assessment.
• Dose changes should only ever be made by your prescriber, based on your individual response and tolerability, never adjusted independently.

How Wegovy Supports Weight Loss

Wegovy contains semaglutide, which mimics the GLP-1 hormone involved in appetite regulation. It can help people feel fuller, reduce hunger and decrease food intake. It also affects stomach emptying, although the extent of this effect varies over time and between individuals.

Wegovy Dosage Chart for Weight Loss

Treatment usually begins at 0.25 mg once weekly, with the dose increased at intervals of four weeks as prescribed. The 7.2 mg dose is not intended for everyone: it may be considered for eligible adults with obesity after they have reached and spent at least four weeks on the 2.4 mg dose. Never increase your dose or change your injection schedule without guidance from your prescriber.

What Dose of Wegovy Is Best for Weight Loss?

The standard 2.4mg maintenance dose is the level at which Wegovy's licensed weight-management outcomes are based, since this is the dose used in the major trials supporting its approval. In the major STEP 1 trial, adults treated with semaglutide 2.4 mg alongside lifestyle interventions lost an average of approximately 14.9% of their starting body weight over 68 weeks. Individual results varied, and this figure should not be treated as a guaranteed outcome or a prediction for every patient.

Does a Higher Dose Mean More Weight Loss?

Generally, yes, at a population level; higher doses within the licensed range are associated with greater average weight loss in the trial data behind Wegovy's approval. In the STEP 1 trial, participants receiving semaglutide 2.4 mg lost an average of about 14.9% of their starting body weight, compared with about 2.4% in the placebo group. This represents an average difference of approximately 12.4 percentage points between the groups. Results varied between individuals, and a higher dose should never be pursued without clinical guidance.

It's worth being clear about what this pattern does and doesn't mean. It explains why the titration schedule exists, working toward a dose associated with meaningful average results, but it doesn't mean skipping ahead or rushing the schedule would improve your own outcome; the gradual pace exists precisely because reaching a higher dose safely and sustainably is what the evidence actually supports, not simply reaching a high number as quickly as possible.

Can You Achieve Weight Loss at a Lower Dose?

Yes, for some people. While the major licensed efficacy data specifically reflects the 2.4mg maintenance dose, some people do experience meaningful weight loss before reaching this level, depending on individual response. Whether staying at a lower dose or continuing to titrate upward is appropriate for you is a genuine, individual decision made together with your prescriber, based on how you're responding and tolerating treatment, not something to decide independently.

The Higher-Strength 7.2mg Option

In the UK, a single-dose 7.2 mg Wegovy pen has been authorised for adults with obesity who have a BMI of 30 kg/m² or higher. The higher dose may be considered when appropriate after at least four weeks on the 2.4 mg weekly dose. It is not authorised for weight management in people with a BMI below 30 or for the cardiovascular risk-reduction indication. Your prescriber must decide whether this option is suitable for you.

What Genuinely Determines Your Results

Clinical trials have reported substantial average weight loss with semaglutide, but the results depend on the study, its participants, the treatment duration and how the data are analysed. In the STEP 1 trial, the average reduction was approximately 14.9% of starting body weight over 68 weeks. Your own results may differ.

Starting Treatment in the UK

The online consultation process

Starting Wegovy involves completing an online health questionnaire covering your medical history, current health and weight management goals, along with a body mass index check to assess eligibility for this weight loss treatment. This is reviewed individually by a UK-registered prescriber, who will only approve treatment if it's judged clinically appropriate for you, and who will guide your dosing throughout treatment.

For adult weight management, Wegovy is licensed for people with a BMI of 30 kg/m² or higher, or a BMI of 27 to below 30 kg/m² with at least one weight-related health condition. NHS access follows separate eligibility criteria and service arrangements, so meeting the medicine's licensed criteria does not automatically mean someone qualifies for NHS treatment.

Pricing

Pricing varies by dose and is shown live on the relevant product page; entry-level treatment currently starts from around £109.99. Always check the live product page for the current price before ordering.

Safety Considerations

Dose changes should only ever be made by your prescriber, based on your individual response and tolerability; never adjust your dose independently or more quickly than prescribed. Nausea, diarrhoea, constipation and vomiting are common side effects, particularly during dose escalation. Many episodes are mild to moderate and improve over time, but symptoms can persist. Contact your prescriber if side effects are severe, persistent or make it difficult to drink enough fluids.

This page deliberately avoids specific weight-loss-rate targets, since responsible personalisation depends on an individual clinical assessment, which a GP or prescriber can properly carry out.

Before starting, discuss any medical conditions and other medications with your prescriber so your treatment plan can be assessed safely.

Seek immediate medical attention if you develop persistent, severe abdominal pain, which may indicate pancreatitis. Sudden loss of vision, including partial loss, also requires urgent ophthalmological assessment. People with diabetes and diabetic retinopathy may need closer monitoring during treatment.

Gallstones and gallbladder inflammation are recognised risks during Wegovy treatment. Seek medical advice if you develop persistent abdominal pain, particularly if it is accompanied by fever, vomiting or yellowing of the skin or eyes.

Semaglutide can reduce the risk of major cardiovascular events in eligible adults with established cardiovascular disease and a BMI of 27 kg/m² or higher. This benefit is supported by clinical trial evidence and applies to a specific patient population; it should not be presented as a guaranteed benefit for everyone taking Wegovy for weight loss.

Medical Disclaimer

This content is provided for general information purposes only and does not constitute medical advice. It is not a substitute for a consultation with a qualified healthcare professional. Treatment suitability and dosing depend on an individual clinical assessment carried out by a UK-registered prescriber. Results vary between individuals. If you have concerns about your weight or general health, speak to a pharmacist or prescriber.